A study published in JAMA found that verapamil may have a beneficial effect on the pancreas in children with newly-diagnosed type 1 diabetes, with C-peptide level being 30% higher for the verapamil group compared to placebo after 52 weeks of treatment. Researchers also noted that 17% of participants in the verapamil group and 20% of participants in the placebo group had a nonserious adverse event considered to be related to treatment.
Full Story: MedPage Today (free registration) (2/24)